Get the Stockscreener App
250.65
1.07%
2.66
After Hours:
250.65
Bio Rad Laboratories Inc stock is traded at $250.65, with a volume of 193.09K.
It is up +1.07% in the last 24 hours and up +15.74% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$247.99
Open:
$249.16
24h Volume:
193.09K
Relative Volume:
0.50
Market Cap:
$6.27B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-9.1712
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
+4.01%
1M Performance:
+15.74%
6M Performance:
-23.15%
1Y Performance:
-6.32%
1-Day Range:
$247.53
$252.90
1-Week Range:
$237.42
$254.82
52-Week Range:
$211.43
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
250.65 | 6.27B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-07-23 | Initiated | UBS | Buy |
| Jun-16-23 | Initiated | Wells Fargo | Overweight |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jan-28-22 | Reiterated | Citigroup | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-17-18 | Initiated | Goldman | Buy |
| Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-16-18 | Downgrade | CL King | Buy → Neutral |
| Jul-13-17 | Initiated | Wells Fargo | Outperform |
| Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Hold |
| Oct-13-16 | Initiated | CL King | Buy |
| May-06-15 | Reiterated | Jefferies | Buy |
| Dec-18-09 | Initiated | Maxim Group | Buy |
| Nov-06-09 | Initiated | Jefferies & Co | Buy |
| Jul-17-09 | Initiated | Soleil | Buy |
| Sep-26-07 | Initiated | Banc of America Sec | Buy |
| Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Transfection Reagents and Equipment Market | Driving Gene - openPR.com
Global Gene Expression Analysis Market | RNA Sequencing & PCR - openPR.com
Bio-Rad extends anti-idiotypic antibody and SpyCatcher Reagent ranges for bioanalysis and antibody drug development - Cambridge Network
Global Gel Electrophoresis Equipment Market Surges Amid Rising - openPR.com
DNA Extraction Kits Market Future Business Opportunities - openPR.com
Protein Engineering Market Fueled by AI, Genomics, - openPR.com
Immunohistochemistry Market Trends | Cancer Diagnosis & - openPR.com
How to Take Advantage of moves in (BIO) - news.stocktradersdaily.com
Global Genomics Market Surges Toward USD 115.4 Billion - openPR.com
Genetic Testing Market Surges Amid Rising Demand - openPR.com
Immunohematology Market Booming with Increased Blood Screening Initiatives | Bio-Rad Laboratories, Immucor Inc. - openPR.com
Protein Analyzers Market Projected to Rise with Increased Focus - openPR.com
Biopharmaceutical Processing Equipment and Consumables - openPR.com
One Step RT-qPCR Kits Market Top Companies StudyTakara Bio - openPR.com
Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO) and Ramsay Health Care (OtherRMSYF) - The Globe and Mail
Horseradish Peroxidase Market Size, Share & Trends | Industry - openPR.com
Cell Biology Market Set to Experience Research Technology - openPR.com
5 Analysts Have This To Say About Bio-Rad Laboratories - Nasdaq
Wells Fargo Lowers Price Target for Bio-Rad Laboratories (BIO) | BIO Stock News - GuruFocus
Europe Chromatography Resins Market Size, Outlook 2031 by Key - openPR.com
Wells Fargo Adjusts Price Target for Bio-Rad (BIO), Maintains Eq - GuruFocus
Food Diagnostics Market | Rapid Pathogen & Contaminant - openPR.com
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
Cancer Monoclonal Antibodies Market in 2025-2032 Detailed - openPR.com
Next Generation Sequencing Market to Witness Upsurge in Growth - openPR.com
bio-rad laboratories stock highlighted in cantor fitzgerald report - Investing.com Australia
bio-rad laboratories stock highlighted in cantor fitzgerald report By Investing.com - Investing.com South Africa
Laboratory Proficiency Testing Market Set to Witness - openPR.com
Minimal Residual Disease Testing Market Set to Witness - openPR.com
Enzyme Linked Immunosorbent Assay Market reached US$ 2.14 - openPR.com
Flow Cytometry Market Growth, Trends & Forecast 2025 | Global - openPR.com
Immunohistochemistry Market Detailed in New Research Report - openPR.com
Here’s Why Bio-Rad Laboratories (BIO) Traded Lower in Q1 - Insider Monkey
Global Microarray Market Size, Share & Growth Forecast - openPR.com
How DNA Sequencing Is Revolutionizing Cancer Genomics and Rare - openPR.com
Cell Viability Assays Market 2025 | Techniques, Applications & - openPR.com
High Resolution Melting Analysis Market Detailed in New - openPR.com
Gel Documentation Systems Market Projected to Witness Massive - openPR.com
Cell Signaling Market in 2025-2032 Detailed Study Analysis with - openPR.com
Neuroscience Antibodies and Assays Market Trends, Growth & - openPR.com
Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Learn to Evaluate (BIO) using the Charts - news.stocktradersdaily.com
Bio-Rad Laboratories (NYSE:BIO) Stock Rating Upgraded by Wall Street Zen - Defense World
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Rad Laboratories Inc Stock (BIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Apr 24 '25 |
Option Exercise |
0.00 |
186 |
0 |
196 |
| PINKSTON ARNOLD A | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| PEI MELINDA LITHERLAND | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| HINCKLEY GREGORY K | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| EDWARDS JEFFREY L | Director |
Apr 22 '25 |
Option Exercise |
0.00 |
308 |
0 |
308 |
| Crowley Michael | EVP, GBL Commercial Operations |
Mar 14 '25 |
Option Exercise |
159.32 |
3,000 |
477,960 |
11,171 |
| Crowley Michael | EVP, GBL Commercial Operations |
Mar 14 '25 |
Sale |
247.06 |
3,000 |
741,184 |
8,171 |
0.54%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):